Sep. 30, 2011 Research at Loyola University Chicago Stritch School of Medicine could help lead to new ways to prevent coronary arteries from reclogging after balloon angioplasties.
The latest in a series of studies in this effort is published online ahead of print in Arteriosclerosis, Thrombosis and Vascular Biology, a journal of the American Heart Association. Senior author is Allen M. Samarel, MD, and first author is Yevgeniya E. Koshman, PhD.
In an angioplasty, a tiny balloon is inflated to open a clogged coronary artery. Typically, a stent is deployed to prevent the artery from collapsing after the balloon is deflated.
The procedure itself irritates the interior walls of the artery. In response, smooth muscle cells migrate to the site and form scar tissue. In roughly one-third of cases, the artery reclogs and another angioplasty is needed.
Newer stents release drugs that prevent migration of muscle cells to the site. But these drugs have the unwanted effect of also stopping endothelial cells from moving to the site. Endothelial cells are needed to repair the irritation to the walls of the artery. (The angioplasty removes endothelial cells that line the inside walls of the artery. This increases the risk that clots will form, break loose and cause heart attacks and strokes. Consequently, patients must take anti-clotting medications for months after their angioplasties.)
The Loyola study points to a new strategy for preventing the unwanted migration of muscle cells while allowing the beneficial movement of endothelial cells. The study involved cell cultures as well as rats that had received balloon angioplasties in their carotid arteries.
Researchers focused on two proteins, known as FAK and FRNK. Both proteins are products of the same gene, but have opposite effects: FAK jump-starts the migration of muscle cells to the angioplasty site, while FRNK inhibits such migration. (FAK stands for focal adhesion kinase; FRNK stands for FAK-related nonkinase.)
Introducing FRNK early on in the course of an angioplasty could prevent the migration of artery-clogging muscle cells while allowing the movement of artery-repairing endothelial cells, Samarel said.
Earlier this year, Koshman presented an abstract of the study to the American Heart Association Arteriosclerosis, Thrombosis and Vascular Biology 2011 Scientific Sessions, where it was judged among the top 10 percent of accepted abstracts.
Samarel is the William B. Knapp Professor of Medicine and Physiology and Koshman is a research associate at Loyola University Chicago Stritch School of Medicine. Other co-authors are Miensheng Chu, PhD.; Steven J. Engman, MD, PhD.; Taehoon Kim, MS; Rekha Iyengar, MBA; and Seth Robia, PhD.
The study was supported by the National Institutes of Health and the Dr. Ralph and Marian Falk Medical Research Trust. During the course of the study, Koshman was an American Heart Association postdoctoral fellow and Engman was a heart association predoctoral fellow.
Other social bookmarking and sharing tools:
- Y. E. Koshman, M. Chu, S. J. Engman, T. Kim, R. Iyengar, S. L. Robia, A. M. Samarel. Focal Adhesion Kinase-Related Nonkinase Inhibits Vascular Smooth Muscle Cell Invasion by Focal Adhesion Targeting, Tyrosine 168 Phosphorylation, and Competition for p130Cas Binding. Arteriosclerosis, Thrombosis, and Vascular Biology, 2011; DOI: 10.1161/ATVBAHA.111.235549
Note: If no author is given, the source is cited instead.